5 results match your criteria: "China. 300704@hospital.cqmu.edu.cn.[Affiliation]"
Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction.
Sci Rep
December 2024
Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- The study investigates the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2-i) on heart failure rehospitalization and overall mortality in patients with acute myocardial infarction (AMI).
- Data from ten clinical trials with 15,748 participants were analyzed, showing that SGLT2-i significantly reduced rehospitalization for heart failure but did not significantly impact all-cause mortality, cardiovascular death, or nonfatal myocardial infarction.
- This suggests that while SGLT2-i is beneficial in preventing heart failure rehospitalization for AMI patients, it may not affect overall death rates or other serious heart complications.
Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study.
BMC Pharmacol Toxicol
April 2024
Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, 76# Linjiang Road, Yuzhong District, 400016, Chongqing, China.
Background: Monoclonal antibody therapy for Covid-19 springs up all over the world and get some efficiency. This research aims to explore the treating effect of BRII-196(Ambavirumab) plus BRII-198(Lomisivir) on Covid-19.
Methods: In this retrospective cohort research, patients received standard care or plus BRII-196 /BRII-198 monoclonal antibodies.
Safety and efficacy of non-reduced use of caspofungin in patients with Child-Pugh B or C cirrhosis: a real-world study.
Infection
June 2024
Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, 76# Linjiang Road, Yuzhong District, Chongqing, 400016, China.
Background And Purpose: The need for dose adjustment of caspofungin in patients with hepatic impairment is controversial, especially for those with Child-Pugh B or C cirrhosis. The purpose of this study was to investigate the safety and efficacy of standard-dose caspofungin administration in Child-Pugh B and C cirrhotic patients in a real-world clinical setting.
Patients And Methods: The electronic medical records of 258 cirrhotic patients, including 67 Child-Pugh B patients and 191 Child-Pugh C patients, who were treated with standard-dose of caspofungin at the Second Affiliated Hospital of Chongqing Medical University, China, from March 2018 to June 2023 were reviewed retrospectively.
Efficacy and safety of caspofungin for patients with hepatic insufficiency.
BMC Infect Dis
June 2022
Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Background: To observe the changes of hepatic function and efficacy of conventional dosage of caspofungin in the treatment of patients with different Child-Pugh scores.
Methods: In total, 200 patients (Child-Pugh A group: 66 patients, Child-Pugh B group: 83 patients, Child-Pugh C group: 51 patients) treated with caspofungin from May 2018 to March 2021 in the Second Affiliated Hospital of Chongqing Medical University were enrolled. Main investigation items were as follows: sex, age, weight, duration of treatment, dosage, department, underlying diseases, risk factors for fungal infection, albumin, liver enzyme, total bilirubin, serum creatinine, estimated glomerular filtration rate.
Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A retrospective cohort study.
World J Clin Cases
May 2021
Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Background: The effectiveness of adjunctive corticosteroid use in patients with coronavirus disease 2019 (COVID-19) remains inconclusive.
Aim: To investigate the effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19.
Methods: We conducted a retrospective analysis of the difference in several outcomes between patients with severe COVID-19 who received corticosteroid therapy (the corticosteroid group) and patients with severe COVID-19 who did not receive corticosteroid therapy (the non-corticosteroid group).